FOLH1 and neoplasm: In a more stringent imaging analysis of 50 patients from the phase 2 Lu-PSMA trial using both fluorodeoxyglucose (FDG)- and PSMA-positron emission tomography (PET), patients with low volumes of FDG avid disease had a longer OS than other patients whereas the volume of tumor burden on PSMA PET/CT was not prognostic [9].